Literature DB >> 8851914

The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis.

R E Steinpreis1.   

Abstract

Phencyclidine (PCP) produces a psychotic reaction in humans which closely resembles an acute episode of schizophrenia and has therefore been given an increasing amount of attention as a model for schizophrenia. The present article reviews the behavioral and neurochemical effects of PCP in both humans and animals. Where possible, comparisons are made between the effects of PCP and amphetamine. The merits of the dopamine versus NMDA/PCP receptor mediated expression of PCP-induced psychosis are discussed, as well as the importance of selecting behavioral models which are best suited to model the expression of psychosis, rather than the motor effects of psychotomimetics.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8851914     DOI： 10.1016/0166-4328(95)00162-x

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN： 0166-4328            Impact factor:   3.332


  39 in total

1.  Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats.

Authors:  Nurith Amitai; Athina Markou
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

2.  Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans.

Authors:  Takatoshi Hikida; Hanna Jaaro-Peled; Saurav Seshadri; Kenichi Oishi; Caroline Hookway; Stephanie Kong; Di Wu; Rong Xue; Manuella Andradé; Stephanie Tankou; Susumu Mori; Michela Gallagher; Koko Ishizuka; Mikhail Pletnikov; Satoshi Kida; Akira Sawa
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-03       Impact factor: 11.205

Review 3.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

4.  Clozapine Reverses Phencyclidine-Induced Desynchronization of Prefrontal Cortex through a 5-HT(1A) Receptor-Dependent Mechanism.

Authors:  Lucila Kargieman; Maurizio S Riga; Francesc Artigas; Pau Celada
Journal:  Neuropsychopharmacology       Date:  2011-10-19       Impact factor: 7.853

5.  Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment.

Authors:  Nurith Amitai; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2008-09-08       Impact factor: 3.533

Review 6.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

7.  Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics.

Authors:  Andrea M Bradford; Kevin M Savage; Declan N C Jones; Mikhail Kalinichev
Journal:  Psychopharmacology (Berl)       Date:  2010-07-31       Impact factor: 4.530

Review 8.  Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators.

Authors:  Douglas J Sheffler; Anthony B Pinkerton; Russell Dahl; Athina Markou; Nicholas D P Cosford
Journal:  ACS Chem Neurosci       Date:  2011-04-12       Impact factor: 4.418

9.  Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli.

Authors:  J C Winter; J R Eckler; R A Rabin
Journal:  Psychopharmacology (Berl)       Date:  2003-11-04       Impact factor: 4.530

Review 10.  Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia.

Authors:  Y Chudasama; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.